Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma

Proteasome inhibition with bortezomib is a validated approach to the treatment of multiple myeloma, but drug resistance often emerges and limits its utility in the retreatment setting. To begin to identify some of the mechanisms involved, we developed bortezomib-resistant myeloma cell lines that, un...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kuhn, Deborah J., Berkova, Zuzana, Jones, Richard J., Woessner, Richard, Bjorklund, Chad C., Ma, Wencai, Davis, R. Eric, Lin, Pei, Wang, Hua, Madden, Timothy L., Wei, Caimiao, Baladandayuthapani, Veerabhadran, Wang, Michael, Thomas, Sheeba K., Shah, Jatin J., Weber, Donna M., Orlowski, Robert Z.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2012
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3476538/
https://ncbi.nlm.nih.gov/pubmed/22932796
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-10-386789
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados